Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real‐World Retrospective Study
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/9180273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 05.11.2026. Verfasst von Bárbara Vieira Granja und 6 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The palmoplantar region is a high‐impact area in psoriasis, with a particularly negative impact on patients’ quality of life. Tildrakizumab has shown efficacy, effectiveness, and safety in the treatment of moderate‐to‐severe plaque psoriasis but has limited evidence in high‐impact areas. The aim of this study was to retrospectively investigate the effectiveness of tildrakizumab in palmoplantar psoriasis.
Methods
This was a multicentric, real‐world, retrospective study of patients with generalized psoriasis with palmoplantar involvement treated with tildrakizumab 100 mg. Patient data were collected from clinical records, and psoriasis severity was evaluated using the ppPASI, ppPASI < 3, and ppPASI < 1 as co‐primary endpoints and the PASI, PGA, BSA, and DLQI as secondary endpoints at baseline and at Weeks 28, 40, and 52 of treatment.
Results
Eighteen patients were included. Mean PASI, BSA, and PGA scores showed a marked reduction from baseline (9.7 ± 6.2; 11.0 ± 7.0; 3.3 ± 0.7) to Week 28 (1.5 ± 1.3; 1.5 ± 1.5; 1.4 ± 1.1), with further improvement at Week 40 (0.9 ± 1.0; 0.9 ± 1.0; 0.9 ± 0.7) and stabilization at Week 52 (1.1 ± 2.2; 1.0 ± 1.6; 0.9 ± 1.1). DLQI scores also improved substantially from baseline (15.1 ± 3.9) to Week 28 (3.7 ± 5.4) and Week 40 (1.4 ± 2.4), with a slight increase between Week 40 and Week 52 (2.3 ± 4.3). Mean ppPASI improved from 15.4 ± 11.1 at baseline to 4.8 ± 12.0 at Week 28 and 1.2 ± 1.6 at Week 40, stabilizing at Week 52 (1.5 ± 2.7). The proportion of patients achieving absolute ppPASI < 3 and ppPASI < 1 increased consistently over time, reaching 61%, 77%, and 81% for ppPASI < 3 and 44%, 62%, and 75% for ppPASI < 1 at Weeks 28, 40, and 52, respectively.
Conclusion
This study, one of the few with 52‐week real‐world data specifically in palmoplantar psoriasis, confirms that tildrakizumab is a valuable therapeutic option for the treatment of psoriasis in this location, providing effective disease control.
Zitieren
APA
Granja, B. V., Vide, J., Gomes, N. P., Torres, T., Bastos, P. M., Morais, P., & Magina, S. (2026). Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real‐World Retrospective Study. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/9180273
Vancouver
Granja BV, Vide J, Gomes NP, Torres T, Bastos PM, Morais P, et al. Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real‐World Retrospective Study. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/9180273
BibTeX
@article{Granja2026,
author = {Granja, Bárbara Vieira and Vide, Júlia and Gomes, Nuno Preto and Torres, Tiago and Bastos, Pedro Mendes and Morais, Paulo and Magina, Sofia},
title = {Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real‐World Retrospective Study},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/9180273}
}
EUVIMED